BeiGene Reports Updated Results of Tislelizumab in P-II Study in Chinese Patients with R/R Classical Hodgkin Lymphoma #EHA2019

 BeiGene Reports Updated Results of Tislelizumab in P-II Study in Chinese Patients with R/R Classical Hodgkin Lymphoma #EHA2019

BeiGene Reports Updated Results of Tislelizumab in P-II Study in Chinese Patients with R/R Classical Hodgkin Lymphoma #EHA2019

Shots:

  • The P-II (NCT03209973) study result involves assessing of tislelizumab (200mg, IV, q3w) as a monothx. in 70 patients with R/R to autologous stem cell transplantation (ASCT) or 2L+ r/r cHL
  • The P-II study results: high anti-tumor activity in patients; ORR (87.1%); CR (62.9%); PR (24.3%); @12mos. PFS (73.8%); well tolerated; presented at 24thCongress of the European Hematology Association (EHA)
  • Tislelizumab (BGB-A317) is an IgG4 anti–PD-1 mAb, minimizing the binding of FcγR on macrophages, being developed by BeiGene and Celgene for solid tumors cancer outside Asia (Ex Japan). NMPA has accepted its NDA and has granted PR designation for r/r cHL in China

Click here to read full press release/ article | Ref: Beigene | Image: Switzerland Global Enterprise

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post